Alnylam Pharmaceuticals, Inc. $ALNY Stock Position Decreased by Hantz Financial Services Inc.

Hantz Financial Services Inc. reduced its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 53.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,345 shares of the biopharmaceutical company’s stock after selling 8,538 shares during the period. Hantz Financial Services Inc.’s holdings in Alnylam Pharmaceuticals were worth $1,812,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Danske Bank A S raised its position in Alnylam Pharmaceuticals by 4.9% in the 3rd quarter. Danske Bank A S now owns 67,708 shares of the biopharmaceutical company’s stock worth $16,706,000 after buying an additional 3,153 shares during the last quarter. Allworth Financial LP raised its position in Alnylam Pharmaceuticals by 7.1% in the third quarter. Allworth Financial LP now owns 1,177 shares of the biopharmaceutical company’s stock worth $290,000 after acquiring an additional 78 shares during the period. Eurizon Capital SGR S.p.A. raised its holdings in Alnylam Pharmaceuticals by 6.2% in the 3rd quarter. Eurizon Capital SGR S.p.A. now owns 24,110 shares of the biopharmaceutical company’s stock worth $5,951,000 after purchasing an additional 1,412 shares during the period. Fifth Third Bancorp lifted its position in shares of Alnylam Pharmaceuticals by 15.9% during the 3rd quarter. Fifth Third Bancorp now owns 11,015 shares of the biopharmaceutical company’s stock valued at $2,718,000 after buying an additional 1,514 shares in the last quarter. Finally, Maryland State Retirement & Pension System lifted its holdings in Alnylam Pharmaceuticals by 12.0% during the third quarter. Maryland State Retirement & Pension System now owns 8,000 shares of the biopharmaceutical company’s stock valued at $1,974,000 after purchasing an additional 859 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. TD Cowen lowered their price objective on Alnylam Pharmaceuticals from $482.00 to $354.00 and set a “buy” rating on the stock in a research report on Friday, October 30th. The Goldman Sachs Group dropped their price objective on shares of Alnylam Pharmaceuticals from $536.00 to $320.00 and set a “buy” rating for the company in a research note on Friday, October 30th. Morgan Stanley cut their target price on Alnylam Pharmaceuticals from $300.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Friday, October 30th. Stifel Nicolaus downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $225.00 target price on the stock. in a research note on Thursday, October 29th. Finally, Citigroup lowered their target price on shares of Alnylam Pharmaceuticals from $340.00 to $320.00 and set a “buy” rating for the company in a report on Wednesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $287.57.

View Our Latest Stock Analysis on ALNY

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $149.40 on Thursday. The stock has a market capitalization of $20.01 billion, a PE ratio of 7.76 and a beta of 0.42. The company has a 50 day moving average price of $212.88 and a 200-day moving average price of $273.15. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.43 and a current ratio of 2.48. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $147.58 and a fifty-two week high of $479.79.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.66 by $14.60. Alnylam Pharmaceuticals had a net margin of 52.85% and a return on equity of 155.33%. The firm had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter in the previous year, the firm earned $2.90 EPS. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.85 earnings per share for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Bryan Supran sold 1,758 shares of the stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $226.88, for a total value of $398,855.04. Following the transaction, the executive vice president directly owned 12,807 shares of the company’s stock, valued at approximately $2,905,652.16. This represents a 12.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Company Profile

(Free Report)

Alnylam Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-causing proteins. Founded in 2002 and headquartered in Cambridge, Massachusetts, the company helped advance RNAi from a scientific discovery into a therapeutic approach. Its marketed medicines include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.

Further Reading

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.